1. Home
  2. NUVB

as of 02-06-2026 4:00pm EST

$5.70
+$0.08
+1.42%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Founded: 2018 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 2.9B IPO Year: N/A
Target Price: $10.89 AVG Volume (30 days): 6.5M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.64 EPS Growth: N/A
52 Week Low/High: $1.54 - $9.75 Next Earning Date: 03-05-2026
Revenue: $26,748,000 Revenue Growth: 1137.19%
Revenue Growth (this year): 636.92% Revenue Growth (next year): 191.15%
P/E Ratio: N/A Index: N/A
Free Cash Flow: -190248000.0 FCF Growth: N/A

Latest Nuvation Bio Inc. News

NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing

All NUVB News

Share on Social Networks: